---
schema_version: "secwatch.filing_event.v1"
accession: "0001698530-25-000017"
form_type: "8-K"
ticker: "XCUR"
cik: "0001698530"
company_name: "EXICURE, INC."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T13:59:52.534752+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Exicure reports FY2024 net loss of $9.7M, cash $12.5M, going concern warning

## Summary
- Cash and cash equivalents $12.5M as of Dec 31, 2024, up from $0.8M year-end 2023; management warns liquidity may not last 12 months.
- Net loss of $9.7M for FY2024, compared to net loss of $16.9M in FY2023; decrease driven by lower G&A and asset sale income.
- R&D expenses $0 for FY2024 (from $1.4M) reflecting cessation of all R&D activities; G&A expenses $5.4M (from $11.7M).
- Company continues exploring strategic alternatives, including transactions with potential partners; substantial doubt about going concern.
- Sold clinical product samples and certain assets in 2024 to a private biopharma; no further operational details.

## SEC filing metadata
- accession: 0001698530-25-000017
- form_type: 8-K
- ticker: XCUR
- cik: 0001698530
- company_name: EXICURE, INC.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1698530/000169853025000017/0001698530-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1698530/000169853025000017/xcur-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001698530-25-000017
- JSON: https://secwatch.observer/filing/0001698530-25-000017.json
- Plain text: https://secwatch.observer/filing/0001698530-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.